David-Ioan Florea

Mr. David-Ioan Florea

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in Water
Verified
Journal Article
Open access
PDF file
IBIoana Boeras
Ioana Boeras
ABAlexandru Burcea
Alexandru Burcea
Doru BanaducDoru Banaduc
Doru Banaduc
DFDavid-Ioan Florea
David-Ioan Florea
Angela Curtean-BănăducAngela Curtean-Bănăduc
Angela Curtean-Bănăduc
The aim of this study was to assess the impact of WWTP effluents on the sediment microbial communities throughout the Mureș River. This study shows the existence of an ecological equilibrium between the WWTP effluent disruptors and the resilience of the Mureș River sediment microbiomes, a fact that suggests the river’s stable/balanced ecological status in this regard, partly due to the microbial communities’ resilience to the local impact of WWTP effluents. High-throughput 16S bacterial metabarcoding was used to evaluate the bacterial communities in the sediment. Due to the lotic system’s sediment microbial communities’ sensitivity to environmental changes, we assumed the dependency of these community structures and functions on environmental abiotic and abiotic parameters. The study results show that, although bacterial communities are equally diverse in the three locations (upstream WWTP, WWTP effluents, and downstream WWTP), there is a difference in community structure between the upstream samples and the WWTP samples, while the downstream samples contain a mixture of the upstream and WWTP effluent communities. Just downstream of the WWTP sediment, microbial communities are influenced by the specific input from the WWTP effluents; nevertheless, the river sediment microbiome is resilient and able to further recover its natural microbial composition, as evidenced by the similarity in bacterial community structures at all upstream river locations. This study demonstrates the ecological equilibrium between the WWTP effluent disruptors and the resilience capacity of the Mureș River sediment microbiomes, a fact that indicates the river’s stable/balanced ecological status, in part due to the microbial communities’ resilience to the local impact of WWTP effluents. Based on these findings, a monitoring system should be implemented here in the future.

27 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
PWPatricia Wischmann
Patricia Wischmann
Manuel SternManuel Stern
Manuel Stern
DFDavid-Ioan Florea
David-Ioan Florea
LNLuise Neudorf
Luise Neudorf
YHYassine Haddad
Yassine Haddad
LBLucas Busch
Lucas Busch
Background: The gold standard treatment for peripheral arterial disease (PAD) of the common femoral artery (CFA) is open common femoral endarterectomy (CFAE). Interest in the less invasive endovascular treatment (EVT) is growing due to PAD patients’ frequent co-morbidities. Aims: We aimed to evaluate three-year EVT outcomes in multimorbid PAD patients with severe calcified CFA lesions. Methods: Using the prospectively maintained “all-comers” Duesseldorf PTA Registry, we analysed the three-year outcomes of 150 patients with EVT of the CFA. Between January 2017 and October 2023, 66 patients received a rotational excisional atherectomy (REA) followed by a drug-coated balloon angioplasty (DCB), and 84 patients received a DCB alone. Results: All procedures involved the CFA, 49% additionally involved the proximal superficial femoral artery (SFA), and 10% of the lesions involved the profunda femoris artery (PFA). The procedural success rate was 97% and independent of PAD stage, with a higher level of stent implantation in the DCB group (58% vs. 39%, p < 0.05). The primary patency rate at one year was 83% for REA + DCB and 87% for DCB (p = 0.576), while secondary patency after three years was 97%. The MALE rate at three years was mainly driven by cdTLR (REA + DCB: (20%) vs. DCB: (14%), p = 0.377), while major amputations were low in both groups (REA + DCB: 3% vs. DCB: 1%). Overall, the major adverse cardiovascular events (MACEs) rate at three years was low (REA + DCB: (5%) vs. DCB: (11%), p = 0.170). Conclusions: The EVT of severely calcified CFA lesions is safe and effective, with high three-year patency rates and low rates of major adverse limb events (MALEs) and MACEs. This registry demonstrates that vessel preparation with REA minimizes the need for stenting.

14 November 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
KBKálmán Benedikt Bódis
Kálmán Benedikt Bódis
DFDavid-Ioan Florea
David-Ioan Florea
SGShouheng Goh
Shouheng Goh
NKNicolas Kramser
Nicolas Kramser
TWTobias Wienemann
Tobias Wienemann
PGPTA-DFS Study Group
PTA-DFS Study Group
Background: Peripheral arterial disease (PAD) and local infections increase the risk of non-healing diabetic foot ulcers (DFU) and limb amputations but are treatable by percutaneous transluminal angioplasty (PTA), local wound care and antibiotic therapy. The exact time to treat chronic leg artery stenosis (LAS) and the role of microbiome composition in DFU remain unclear. This study aims to assess whether an early PTA within 48 h after diagnosing a LAS offers advantages over standard care. Methods: The PTA-DFS Study is a randomised controlled monocentric trial including individuals with T2D and DFU, aged > 18 years with haemodynamically relevant chronic LAS. The primary study endpoint is to investigate the impact of the early PTA within 48 h on wound-healing assessed by wound area changes after PTA using a 3D-camera with artificial intelligence (AI)-based wound-analysis-system. The secondary endpoint is the effect of early PTA on the combined occurrence of major adverse limb (MALE) and safety-related cardiac events (MACE) over 12 month post-angioplasty using time-to-event analysis. Additional secondary outcomes are time to complete wound healing, major amputation rate and the need for new revascularization. Explanatory variables for wound healing are wound microbiome changes using whole-genome sequencing and oxygen saturation of the wound environment measured using near-infrared spectroscopy. Data will be collected at baseline, 24 h, 1, 2, 3, 6, and 12 months after PTA. Diabetic kidney disease, distal symmetric polyneuropathy, retinopathy, cardiomyopathy, LAS will be assessed by laboratory analyses, clinical scores, AI-based fundus photography, echocardiography, duplex sonography, and pulse oscillography. Discussion: The PTA-DFS aims to improve diagnostic and therapeutic algorithms, risk assessment and enable tailored therapies for persons with T2D and ischemic DFU. Trial registration: Trial Registration Number: NCT06124586 (Registration Date: 2023–08-2).